Also found in: Thesaurus, Medical, Financial, Encyclopedia, Wikipedia.


 (ĭm′yə-nō-tŏk′sĭn, ĭ-myo͞o′-)
A hybrid molecule formed by binding a toxin to a monoclonal antibody, used to destroy tumor cells.


a toxin with immunosuppressive effects


(ˌɪm yə noʊˈtɒk sɪn, ɪˌmyu-)

a monoclonal antibody linked to a toxin with the intention of destroying a specific target cell while leaving adjacent cells intact.
Mentioned in ?
References in periodicals archive ?
Immunotoxin refers to a toxin with the targeting part being either an intact monoclonal antibody (mAb) or its fragment.
Phase I study of SS1P, a recombinant anti-mesothelin immunotoxin given as a bolus I.
Solicitation: Production Of Pegylated Immunotoxin For Pre-Clinical Cancer Studies
2000) Site-specific chemical modification with polyethylene glycol of recombinant immunotoxin anti-Tac(Fv)-PE38 (LMB-2) improves antitumor activity and reduces animal toxicity and immunogenicity.
Administration of a CD25-directed immunotoxin, LMB-2, to patients with metastatic melanoma induces a selective partial reduction in regulatory T cells in vivo.
IL-2 immunotoxin therapy modulates tumor-associated regulatory T cells and leads to lasting immune-mediated rejection of breast cancers in neutransgenic mice," The Journal of Immunology, vol.
Stirpe, "T lymphocyte killing by a xanthine-oxidase-containing immunotoxin," Cancer Immunology, Immunotherapy, vol.
Cytotoxic activity of the recombinant anti-mesothelin immunotoxin, SS1(dsFv)PE38, towards tumor cell lines established from ascites of patients with peritoneal mesotheliomas.
Half of the animals subsequently received a two-week dose of a genetically designed, HIV-specific poison, or immunotoxin, to complement the antiretrovirals, while the other half continued receiving antiretrovirals alone.
Moreover, lintuzumab conjugated with immunotoxin recombinant gelonin (HUM-195/rGEL) has been under investigation in patients with relapsed/refractory myeloid leukemias [108].
Expression of HER2 in human gastric cancer cells directly correlates with antitumor activity of a recombinant disulfide stabilized anti-HER2 immunotoxin.
Additionally, multiple INDs are expected in the next 12-24 months resulting from preclinical and discovery work underway to advance multiple antibody, immunotoxin, and protein decoy candidates, systemic delivery and a next generation RheoSwitch Therapeutic System(R).